Chemodex

Osthole

CHF 81.00
In stock
CDX-O0097-M01010 mgCHF 81.00
CDX-O0097-M05050 mgCHF 189.00
More Information
Product Details
Synonyms 7-Methoxy-8-(3-methyl-2-butenyl)coumarin; 7-Methoxy-8-isopentenylcoumarin; NSC 31868
Product Type Chemical
Properties
Formula C15H16O3
MW 244.29
CAS 484-12-8
RTECS GN7700000
Source/Host Chemicals Synthetic
Purity Chemicals ≥95% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO, DMF, ethanol (all 20mg/ml) or methanol (10mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key MBRLOUHOWLUMFF-UHFFFAOYSA-N
Smiles O=C1OC2=C(C/C=C(C)/C)C(OC)=CC=C2C=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at RT.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Osthole is a natural coumarin that was first isolated from several medicinal plants, including C. monnieri and A. pubescens. Osthole exhibits immunomodulatory, antioxidative, and anti-inflammatory properties, by regulating the expression of TNF-α, NF-κB, TGF-β, cyclooxygenases, leukotrienes, nitric oxide, ERK and JNK. Shows also anti-cancer, chemopherapeutic, analgesic, neuroprotective, antipruritic, anti-leishmania and anti-lipedemic activities. It is reported to induce a nonspecific elevation of cAMP and cGMP levels through its ability to inhibit phosphodiesterases, which leads to a modulation of calcium channel signaling and vasorelaxant effects. Selectively inhibits TRPV3 channels in skin. Induces apoptosis and cell cycle arrest in cancer cells. Suppression of fatty acid synthase expression in HER2-overexpressing breast cancer cells indicates osthole as a promising agent for chemotherapy.

Product References

(1) R.L. Huang, et al.; Hepatology 24, 508 (1996) | (2) L. Wang, et al.; J. Biomed. Res. 29, 132 (2015) | (3) Z.R. Zhang, et al.; Evid.-Based Complem. Altern. Med. 2015, 919616 (2016) | (4) E.K. Kermani, et al.; Pharmacognosy Res. 8, S1 (2016) | (5) X.M. Xu, et al.; Oncol. Lett. 12, 3779 (2016) | (6) Y. Che, et al.; Oncol. Rep. 40, 737 (2018) | (7) X.Y. Sun, et al.; Mol. Pharmacol. 94, 1164 (2018) | (8) Y. Yao, et al.; Life Sci. 217, 16 (2019)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.